Cystic Fibrosis Foundation 5
5 · BiomX Inc. · Filed Mar 4, 2025
Insider Transaction Report
Form 5
BiomX Inc.PHGE
Cystic Fibrosis Foundation
10% Owner
Transactions
- Conversion
Common Stock, par value $0.0001 per share
2024-07-15+854,700→ 1,787,758 total - Conversion
Series X Preferred Stock
2024-07-15−8,547→ 13,088 total→ Common Stock (854,700 underlying)
Footnotes (3)
- [F1]Reflects a ten-for-one reverse stock split of the Issuer's common stock that was effected on August 26, 2024 (the "Reverse Split").
- [F2]In accordance with the Certificate of Designation of Preferences, Rights and Limitations (the "Certificate of Designation") governing the Series X Non-Voting Convertible Preferred Stock ("Series X Preferred Stock"), on July 15, 2024 (the "Stockholder Approval Date"), 8,547 shares of Series X Preferred Stock held by the Reporting Person automatically converted into 8,547,000 shares of Common Stock; following the Reverse Split, such shares were combined to 854,700 shares of Common Stock.
- [F3]As of the third business day after the Stockholder Approval Date, each share of Series X Preferred Stock became convertible at any time at the election of the holder into 100 shares of Common Stock (as adjusted pursuant to the Reverse Split, and subject to further adjustment), subject to a beneficial ownership limitation, in accordance with the Certificate of Designation. The Series X Preferred Stock has no expiration date.